Fortress Biotech stock (US32015L1035): Q1 earnings miss on revenue, but EMROSI shows momentum

Fortress Biotech reported Q1 2026 earnings on May 13, missing revenue expectations with $6.3 million versus consensus, though its EMROSI dermatology asset posted strong prescription growth.

Fortress Biotech reported first-quarter 2026 earnings on May 13, 2026, posting a net loss of $2.2 million, or $0.08 per share, compared to a net loss of $4.1 million, or $0.18 per share, in the prior year period, according to MarketBeat as of May 13, 2026. The company's Q1 revenue reached $6.3 million, driven primarily by EMROSI, its dermatology asset, which generated strong momentum with prescriptions rising to approximately 30,000, up sequentially and well ahead of the prior year.

The stock closed at $2.23 USD on May 13, 2026, on Nasdaq, according to MarketBeat as of May 13, 2026. Selling, general and administrative expenses declined to $10.1 million for the quarter compared to $10.6 million in the first quarter of 2025, reflecting improved operational efficiency.

As of: May 14, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Fortress Biotech Inc
• Sector/industry: Biopharmaceuticals
• Headquarters/country: New York, United States
• Core markets: Oncology, rare diseases, dermatology
• Key revenue drivers: EMROSI (dermatology), portfolio of subsidiaries
• Home exchange/listing venue: Nasdaq (FBIO)
• Trading currency: USD

Fortress Biotech: diversified biopharmaceutical holding company

Fortress Biotech operates as an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term shareholder value through product revenue, equity holdings, and dividend and royalty income. The company is headquartered in New York and operates through a network of majority-owned subsidiaries targeting areas of high unmet medical need, including oncology, rare diseases, and dermatology. This diversified portfolio approach allows Fortress to balance risk across multiple therapeutic areas while maintaining exposure to high-growth segments within the biopharmaceutical industry.

Q1 2026 financial performance and EMROSI momentum

In the first quarter of 2026, Fortress Biotech's EMROSI dermatology asset delivered the strongest revenue contribution, with prescriptions reaching approximately 30,000, representing sequential growth and significant year-over-year improvement. The company reported total Q1 revenue of $6.3 million, with the net loss narrowing substantially to $2.2 million compared to $4.1 million in the prior year period. Operating expenses improved, with SG&A expenses declining to $10.1 million from $10.6 million in Q1 2025, demonstrating cost discipline as the company scales its commercial operations.

The earnings report highlighted positive sentiment around EMROSI's commercial trajectory, with prescription volumes rising both sequentially and year-over-year, signaling market acceptance and growing demand for the dermatology treatment. This momentum in a core revenue driver provides a foundation for potential revenue acceleration in subsequent quarters, though the company's overall financial position remains in loss territory as it continues to invest in pipeline development and subsidiary operations.

Conclusion

Fortress Biotech's Q1 2026 results reflect a company in transition, with narrowing losses and improving operational efficiency offset by modest absolute revenue levels. The strong momentum in EMROSKI prescriptions provides a near-term growth catalyst, though investors should monitor whether the company can sustain this trajectory and expand its revenue base across its diversified subsidiary portfolio. The stock's performance will likely depend on continued commercial execution in dermatology and progress within its oncology and rare disease pipelines.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.